LivaNova (NASDAQ:LIVN) Stock Price Target Raised at Needham & Company LLC

Key Points

• Needham raised LivaNova’s price target to $112 from $93 and maintained a Buy rating, implying 14.17% upside from the share price cited in the report.
• LivaNova beat quarterly estimates, reporting EPS of $1.23 and revenue of $393.1 million, up 9.9% year over year; the article also says the company raised its full-year EPS guidance.
• The stock climbed 22.8% on Wednesday to $98.10. Analysts’ overall consensus rating was Moderate Buy, with an average price target of $90.12.

LivaNova (NASDAQ:LIVN - Get Free Report) had its target price upped by Needham & Company LLC from $93.00 to $112.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's price objective would indicate a potential upside of 14.17% from the stock's current price.

A number of other brokerages have also recently issued reports on LIVN. Weiss Ratings upgraded shares of LivaNova from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, October 27th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday, August 5th. Barclays raised LivaNova to a "strong-buy" rating in a research note on Wednesday, October 7th. Mizuho upped their price objective on LivaNova from $90.00 to $95.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Finally, Zacks Research downgraded LivaNova from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, LivaNova has an average rating of "Moderate Buy" and a consensus price target of $90.12.

LivaNova Trading Up 22.8%

NASDAQ LIVN traded up $18.20 on Wednesday, reaching $98.10. The company had a trading volume of 1,770,677 shares, compared to its average volume of 735,428. LivaNova has a 52 week low of $48.82 and a 52 week high of $98.13. The stock's 50 day moving average is $78.56 and its 200-day moving average is $73.10. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The stock has a market cap of $5.40 billion, a price-to-earnings ratio of 28.98 and a beta of 0.91.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.06 by $0.17. The firm had revenue of $393.10 million for the quarter, compared to analysts' expectations of $381.13 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The company's revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.11 earnings per share. Equities analysts predict that LivaNova will post 3.78 earnings per share for the current year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $78.01, for a total value of $273,035.00. Following the transaction, the director directly owned 4,434 shares of the company's stock, valued at $345,896.34. This represents a 44.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brooke Story sold 2,300 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director owned 7,488 shares in the company, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 7,450 shares of company stock worth $591,839. 0.35% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LIVN. AlphaCore Capital LLC acquired a new position in LivaNova in the 3rd quarter valued at approximately $308,000. Hohimer Wealth Management LLC raised its position in LivaNova by 5.4% during the 3rd quarter. Hohimer Wealth Management LLC now owns 4,277 shares of the company's stock worth $327,000 after purchasing an additional 219 shares during the last quarter. Alamar Capital Management LLC bought a new position in LivaNova during the 3rd quarter worth $1,814,000. Covestor Ltd lifted its holdings in LivaNova by 135.1% during the 3rd quarter. Covestor Ltd now owns 1,300 shares of the company's stock worth $99,000 after buying an additional 747 shares during the period. Finally, Vise Technologies Inc. lifted its holdings in LivaNova by 40.3% during the 3rd quarter. Vise Technologies Inc. now owns 3,915 shares of the company's stock worth $299,000 after buying an additional 1,124 shares during the period. Institutional investors own 97.64% of the company's stock.

More LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q3 adjusted earnings were $1.23 per share, ahead of analyst estimates of roughly $1.03–$1.06 and up from $1.11 a year earlier. LivaNova Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Revenue rose 9.9% year over year to $393.1 million, exceeding estimates of about $381 million. LivaNova delivers Q3 revenue of $393.1M, up 9.9%
• Positive Sentiment: The company raised its full-year EPS guidance, adding to the earnings beat as a potential support for investor expectations. The articles provided did not specify the revised guidance range. LivaNova beats Q3 2026 estimates and raises full-year EPS guidance

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company's Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.